drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Autologous, gene-modified CD19-directed chimeric antigen receptor (CAR) T-cell therapy derived from the patient's T cells and given as a single infusion to deplete CD19+ B cells and reduce autoantibody production in SLE.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express a CD19-specific chimeric antigen receptor; upon binding CD19 on B-lineage cells, the CAR T cells activate, proliferate, and kill CD19+ cells via cytotoxic mechanisms, depleting B cells and reducing autoantibody production to reset humoral autoimmunity.
drug_name
SCRI-CAR19v3
nct_id_drug_ref
NCT06465147